[Cerebrolysin in treatment of acute ischemic stroke].
Cerebrolysin is composed of low molecular peptides and free amino-acids and as a nootropic drug it administered in various diseases of central nervous system. In an open clinical trial patients with acute ischaemic stroke in the region of the middle cerebral artery, were treated. Cerebrolysin was administered as intravenous infusion in daily dose of 15 ml during 21 days. Recovery in 10 patients and improvement in 3 was obtained and only one patient died. The results were compared to the large group of 108 patients treated earlier with other drugs. Therapeutic effect was similar in all groups.
Domzał
T
T
Kliniki Neurologicznej CSK WAM w Warszawie.
Zaleska
B
B
D000368:Aged; D000596:Amino Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D000628:Aminophylline / Q000627:therapeutic use; D002545:Brain Ischemia / Q000188:drug therapy*; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use; D014748:Vinca Alkaloids / Q000627:therapeutic use
D000596:Amino Acids; D014665:Vasodilator Agents; D014748:Vinca Alkaloids; D000628:Aminophylline; C006952:cerebrolysin; C013983:vinpocetine
Cerebrolizyna w leczeniu niedokrwiennych udarów mózgowych.